Collaboration - July 23, 2014
MedImmune teams up with Advaxis
MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies. The two companies will collaborate on a Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’ lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent […]
Collaboration - March 13, 2014
Medimmune collaborates with University of Cambridge
Medimmuneand the University of Cambridge have entered into a three-year oncology research collaboration. The aim of the partnership is to advance cancer research by using imaging technologies to measure key biologic changes within growing tumours. Under the agreement, Medimmune will contribute both funding and a post-doctoral scientist to work within the laboratory of Professor Kevin Brindle at […]
Collaboration - January 8, 2014
Immunocore, MedImmune sign oncology research collaboration and licensing agreement
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell […]
Acquisition - August 26, 2013
MedImmune buys Amplimmune
The AstraZeneca unit MedImmune acquires US biotech company for up to $500 million. Amplimmune is based in Maryland and focuses on developing novel therapeutics in cancer immunology. According to AstraZeneca, the acquisition will bolster MedImmune’s oncology pipeline by obtaining multiple early-stage assets for its immune-mediated cancer therapy (IMT-C) portfolio, including AMP-514, an anti-programmed cell death 1 (PD-1) monoclonal […]
Biotech Business - April 29, 2013
MedImmune acquires AlphaCorePharma
AstraZeneca’s global biologics R&D arm MedImmune has acquired AlphaCorePharma. The Michigan-based biotech company focuses on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme. Cardiovascular and metabolic disease is a core therapy area for AstraZeneca’s small and large molecule research. “As the science in this area continues to evolve, we are committed to […]
